News | February 24, 2026
Bayer introduces chemo-free treatment option for advanced prostate cancer in India
Prostate cancer is one of the fastest-growing cancers in India, with approximately 37,948 new cases each year
Prostate cancer is one of the fastest-growing cancers in India, with approximately 37,948 new cases each year
The approval follows the pivotal Phase III ARANOTE trial, which demonstrated that darolutamide plus ADT cut the risk of radiological progression or death by 46% compared to placebo plus ADT
XTANDI is the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in this patient population, supporting its earlier use in this setting
European Commission granted approval of darolutamide in combination with androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC)
Xtandi is approved in over 80 countries, including the U.S., EU, and Japan
Five-year follow-up data from the Phase 3 ARCHES trial shows XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces risk of death by 30%
Apalutamide is an androgen receptor inhibitor indicated for the treatment of patients with metastatic castration-sensitive prostate cancer
Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
Enzalutamide Tablets will be produced at the Group’s manufacturing site at SEZ, Ahmedabad
Subscribe To Our Newsletter & Stay Updated
